HemaQuest Lands Series B Extension Funding Worth $13M

HemaQuest Pharmaceuticals, Inc. recently gained $13 million worth of extension funding for their Series B round. This additional financing was participated in by Aberdare Ventures, Forward Ventures, and Lilly Ventures. Other existing investors like De Novo Ventures and Latterell Venture Partners also took part in this extension.

The company’s Chief Financial Officer, Tamara Seymour, recently shared a bit more about the company in this recent e-interview with Lead411:

Who are your competitors and how are you different from them?

There is one generic drug, Hydroxyurea, approved for use in reducing
pain crises and hospitalizations for sickle cell patients.

What percentage of your marketing budget are spent on the

Our drug candidate is in clinical development for sickle cell
disease. We have no marketed products.

A. Advertising
B. Social Media Marketing
D. PR – Minimal
E. Direct Marketing –
F. Other –

What do you plan to spend your new funding on? Product
development? Marketing?

Phase 2b of our drug candidate, HQK-1001, for
patients with sickle cell disease.

If this is your first round of financing and you’re the CEO, how
many hours did you put into working on getting your financing? Was that taking up the most of your day?

This is an extension of a Series B so it is not the first round.

If you are the CEO, what are your biggest challenges?

The clinical risk associated with running a phase 2b

How many employees do you have?


When were you founded?


Want to read more about their recent funding? You can check on their press release here.

About Christine Guinto

Christine Guinto is our part-time writer for the Lead411 Blog. She specializes in our funding news. You can contact her at christine [at] lead411.net. Christine Amos on Google+!